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Background: As a result of the focus on vital functions in patients with brain damage, dermatological
symptoms are often overlooked during their period of admission to hospital. However, patients with
brain damage are more likely to have dermatological diseases than the general population and other
inpatients for various reasons, including immobilization, treatment with multiple drugs, long-term
hospitalization, and their immunocompromised status.
Objectives: The purposes of this study were: (1) to analyze the frequency and characteristics of
dermatological consultations among patients who were admitted to hospital as a result of brain damage;
and (2) to compare these ﬁndings with other reports about inpatient dermatological consultations.
Methods: We analyzed data for 240 patients with brain damage who attended our department of
dermatology between January 1, 2007 and December 31, 2011. The total numbers of male and female
patients were 132 (55%) and 108 (45%), respectively (male to female ratio 1.22:1). We retrospectively
reviewed medical records, demographic information, reason for dermatological consultation, and the
diagnosis of the dermatoses.
Results: The age group most frequently seen was patients in the 7th decade of life and the most common
underlying brain injury was traumatic intracranial hemorrhage. The mean standard deviation score on
the Glasgow Coma Scale (GCS) was 6.8 3.0. When the levels of brain damage of the patients were
classiﬁed using the GCS, 68.3% of the patients were in the severe (GCS 8) category. The most common
skin disorders were seborrheic dermatitis (17.9%), followed by mycoses (15.5%), and drug-induced skin
eruption (13.2%).
Conclusion: The characteristics of dermatological consultations in patients with brain damage may be
different from those of other inpatients attending dermatological clinics. The analysis of dermatological
disorders in patients with brain damage can assist in understanding the “braineskin connection”.
Copyright  2013, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Although the practice of dermatology has recently become a pre-
dominantly outpatient-based specialty, there continues to be a
need for dermatological expertise within hospitals, where patients
have a wider spectrum of severe and serious dermatological dis-
orders associated with signiﬁcant morbidity.1,2 Many patients who
are admitted to hospital for various nondermatological diseases
often have underlying skin disease, whereas others develop acute
dermatological problems during their stay in hospital. These gen-
eral illnesses contribute to developing and worsening the primaryy have no ﬁnancial or non-
tter or materials discussed in
y, Kangbuk Samsung Hospi-
th Korea.
iwanese Dermatological Associatiodermatological diseases; the management of an underlying disease
can also cause dermatological disease.
Patients with brain damage due to various causes, such as intra-
cranial hemorrhage, hypoxia, metabolic disease, infection, or tumor,
may have many dermatological problems, but these are often over-
looked during their stay in hospital because of many other compli-
cated medical problems. However, it is still important for doctors to
have a consultationwith patients with brain damage regarding their
skin problems. Such patients are especially vulnerable to drug-
induced skin eruptions or infections due to the administration of
many different drugs and exposure to immunocompromised condi-
tions including underlying disease and long term steroid use.
Several recent studies have independently shown that our skin
is an unexpectedly prominent target organ for numerous neuro-
endocrine, neurotrophic, neurotransmitter, and neuropeptide sig-
nals, which have a profound effect on skin biology in health and
disease.3 The aim of this study was to characterize the proﬁles of
patients with brain damage and the scope and referral pattern ofn. Published by Elsevier Taiwan LLC. All rights reserved.
Table 2 Causes of brain damage in patients referred to a dermatologist.
Cause of brain damage Patients, n (%) Mean GCS score
Intracranial hemorrhage
Traumatic intracranial hemorrhage 121 (50.4) 5.0
Spontaneous intracranial hemorrhage 69 (28.7) 7.7
Hypoxia 25 (10.4) 9.3
Metabolic disease 11 (4.6) 9.8
Brain tumor 6 (2.5) 10.6
Infectious disease 7 (2.9) 8.6
Total 240 6.8a
GCS ¼ Glasgow Coma Scale.
a Average score of all patients.
J. Lee et al. / Dermatologica Sinica 32 (2014) 133e136134dermatology consultations in a tertiary hospital, which has not
previously been well studied.
Patients and methods
All consultations with patients in hospital were referred to the
Department of Dermatology, Kangbuk Samsung Hospital, Sung-
kyunkwan University School of Medicine, Seoul, Korea, between 1
January, 2007 and 31 December, 2011. The data were collected
retrospectively from the admission and daily progression notes
provided by the attending doctor and the consultation notesmade by
the dermatological consultant. Final diagnoses were classiﬁed ac-
cording to the English version of the International Statistical Classi-
ﬁcation of Diseases and Related Health Problems (ICD-10).4 Only the
dermatological disorder responsible for the consultation was recor-
ded. During weekdays, each request was allocated to one of three
different dermatology consultants, assisted by a 3rd-year derma-
tology resident. A potassium hydroxide smear test from skin scrap-
ings, swabs for bacterial culture, and biopsy samples were taken as
appropriate by the dermatologist to reach a deﬁnitive diagnosis. The
severity of brain damage was classiﬁed into three groups (severe,
moderate, and mild) based on the Glasgow Coma Scale (GCS) and
these scores were evaluated by the attending doctors.
All statistical analyses were performed using SPSS 12.0 (SPSS
Inc., Chicago, IL, USA). Absolute and relative frequencies were
analyzed for all data. Continuous variables, such as age, were
expressed as mean values with standard deviations. The difference
in the prevalence of skin disease according to the GCS score was
evaluated by the Chi-square test. In all instances, p < 0.05 was
considered signiﬁcant.
Results
During the 5-year study period, 240 patients who presented with
altered consciousness due to brain damage were referred to the
dermatologists. We diagnosed 341 dermatological diseases, per-
formed 45 skin biopsies, 11 bacterial cultures, 67 potassium hy-
droxide smear tests, and 13 dermatological procedures of various
kinds (cryotherapy, intralesional injection, and wet dressing).
Ninety-ﬁve patients (39.6%) were seen twice by a dermatologist for
different dermatological symptoms. The most frequent age group
was the patient’s 7th decade of life (25.3%) and the next most
frequent was the 6th decade (19.5%) (Table 1).
The most frequent cause of brain damage was traumatic intra-
cranial hemorrhage (50.4%), followed by spontaneous intracranial
hemorrhage (28.7%), hypoxia (10.4%), metabolic disease (4.6%), in-
fectious disease (2.9%), and brain tumors (2.6%) (Table 2). The most
frequent diagnosis was seborrheic dermatitis (ICD-10:L21; 17.9%),
mycoses (ICD-10:B35w37; 15.5%), drug-induced skin eruption (ICD-
10:L27.0, 27.1; 13.2%), xerosis cutis (ICD-10:L85.3; 9.1%), irritant
contact dermatitis (ICD-10:L24; 5.3%), and pruritus (ICD-10:L29;
4.4%) (Table3). It took ameanof 39.4days for seborrheic dermatitis to
become symptomatic and for the patient to be seen by a dermatol-
ogist after initial brain damage, 31.4 days for mycoses, 15.0 days for
drug-induced skin eruption, and 47.1 days for xerosis cutis.Table 1 Demographic data of 240 patients (age, sex).
Age (y) Men (n ¼ 132) Women (n ¼ 108) Total, n (%) (n ¼ 240)
<30 4 5 9 (3.7)
30e39 10 10 20 (8.3)
40e49 18 18 36 (15)
50e59 29 18 47 (19.5)
60e69 36 25 61 (25.3)
70e79 25 21 46 (19.2)
80 10 11 21 (9)Based on the level of brain damage using the GCS, 68.3% of pa-
tients were at the severe (GCS 8) level (Table 4). The most com-
mon dermatological diseases in the severe group were mycoses
(24.9%), seborrheic dermatitis (20.6%), and drug-induced skin
eruption (18%). For the 25.5% of patients in the moderate
(9GCS 12) group, the common diseases were seborrheic
dermatitis (20.6%), pruritus (13.8%), and drug-induced skin erup-
tion (12.6%). For the 6.2% of patients in the mild (GCS 13) group,
the common diseases were seborrheic dermatitis (28.6%), pruritus
(14.3%), and herpes simplex (14.3%). The incidence of mycoses is
statistically signiﬁcantly higher in the severe group (p< 0.01).Discussion
The dermatological diseases of patients with brain damage are
often overlooked during their period of admission to hospital
because of many other complicated medical problems. Patients
with brain damage have difﬁculty in describing their symptoms
because of an alteration in consciousness, and this tends to delay
diagnosis. However, we should also consider the fact that the op-
portunity to develop dermatological problems is relatively high in
patients with brain damage. Decreased movement, altered immu-
nity, and long-term stays in hospital provide suitable conditions for
the growth of microorganisms, and treatment with antibiotics or
aromatic anticonvulsant drugs (e.g. carbamazepine, phenytoin,
phenobarbital, primidone, and oxcarbazepine) can cause severe
adverse drug reactions. In particular, a recent study has shown that
the central nervous system and the skin are connected by various
mechanisms.3 The fact that the skin and nervous system develop
from the same embryological origin, share common molecular
syntax, and communally utilize the immune system to provide
signals and regulation, is generally acknowledged.3,5 The central
nervous system is directly or indirectly connected to the func-
tioning of skin.5 The direct connection is via efferent nerves or
mediators derived from the central nervous system, and the indi-
rect connection is via the adrenal glands or immune cells.5 We thus
speculate that damage of the central nervous system can contribute
to the development of dermatological diseases.
In our study, 68.3% of the patients who were seen by a derma-
tologist had a severe alteration of consciousness. We believe that
dermatological disease is likely to occur when a patient’s brain
damage is severe. The severe brain damage can cause immobili-
zation. In addition, the patients with more severe brain damage
tend to be treated with a larger number of drugs, such as anti-
convulsant drugs, antibiotics, and diuretics.
The most frequent diagnosis was seborrheic dermatitis in 17.9%
of the patients. Previous reports for a diagnosis of seborrheic
dermatitis ranged from 3.1% to 5.2% of patients referred to a
dermatologist.2,6 It has long been recognized that patients with
Parkinson’s disease andmood disorder who have been treatedwith
neuroleptic drugs often develop seborrheic dermatitis.7 The
Table 3 Diagnoses (ICD-10 code).4
Disease Patients, n (%) GCS score Duration (d)
Infections of the skin and subcutaneous tissue
Cellulitis (L03.X) 3 (0.9) 5.3
Cutaneous abscess, furuncle and carbuncle (L02.X) 1 (0.1) 7.0
Viral infections characterized by skin and mucous membrane lesions 12 (3.5) 18.1
Herpes simplex (B00.1) 9 7.2
Zoster (B02) 3 4.0
Mycoses 53 (15.5) 4.9 31.4
Dermatophytosis (B35) 21 5.6
Other superﬁcial mycoses (B36) 3 9.3
Candidiasis (B37) 29 4.0
Scabies (B86) 1 (0.3) 5.0
Neoplasms 12 (3.5)
Melanoma and other malignant neoplasms of skin (C43-C44) 3 4.7
Kaposi’s sarcoma (C46) 1 6.0
Benign neoplasms 3 11.7
Carcinoma in situ of skin (D04) 2 11.5
Secondary malignant neoplasm of skin (L79.2) 3 4.7
Endocrine, nutritional and metabolic diseases
Metabolic disorders (E70eE90) 1 (0.3) 3.0
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Allergic purpura (D69.0) 3 (0.9) 7.7
Diseases of the circulatory system
Phlebitis and thrombophlebitis (I80) 4 (1.2) 7.8
Venous insufﬁciency (chronic) (peripheral) (I87.2) 2 (0.6) 11.0
Diseases of the digestive system
Other diseases of lip and oral mucosa (K13) 2 (0.6) 3.5
Pregnancy, childbirth and the puerperium
Other maternal disorders predominantly related to pregnancy (O20eO29) 2 (0.6) 8.0
Diseases of the skin and subcutaneous tissue
Bullous disorders (L10eL14) 1 (0.3) 12.0
Dermatitis and eczema
Seborrheic dermatitis (L21) 61 (17.9) 6.9 39.4
Diaper (nappy) dermatitis (L22) 7 (2.1) 4.5
Allergic contact dermatitis (L23) 11 (3.2) 6.9
Irritant contact dermatitis (L24) 18 (5.3) 8.0
Dermatitis due to substances taken internally (drug eruption) 45 (13.2) 15.0
Generalized skin eruption due to drugs and medications (L27.0) 32 (9.4) 5.6
Localized skin eruption due to drugs and medications (L27.1) 13 (3.8) 7.4
Lichen simplex chronicus and prurigo (L28) 3 (0.9) 10.7
Pruritus (L29) 15 (4.4) 10.0
Papulosquamous disorders
Psoriasis (L40) 2 (0.6) 9.5
Urticaria and erythema
Urticaria (L50) 10 (2.9) 7.8
Erythema multiforme (L51) 6 (1.8) 5.8
Erythema nodosum (L52) 2 (0.6) 6.0
Other erythematous conditions (L53) 3 (0.9) 8.7
Disorders of skin appendages
Nail disorders (L60) 2 (0.6) 8.5
Acne (L70) 4 (1.2) 8.3
Other follicular disorders (L73) 4 (1.2) 7.5
Other disorders of the skin and subcutaneous tissue
Corns and callosities (L84) 2 (0.6) 12.5
Xerosis cutis (L85.3) 31 (9.1) 6.9 47.1
Lupus erythematosus (L93) 1 (0.3) 10.0
Vasculitis limited to skin, not elsewhere classiﬁed (L95) 5 (1.5) 6.2
Chronic ulcer of skin, not elsewhere classiﬁed (L98.4) 3 (0.9) 8.7
Amyloidosis of skin (L99) 1 (0.3) 9.0
Medical devices associated with adverse incidents in diagnostic and therapeutic use (Y70eY82) 8 (2.3) 8.9
Total 341 6.8
GCS ¼ Glasgow Coma Scale.
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may result in changes in various neuromediators and aggravate
dermatitis. Furthermore, using various neuroleptic drugs in pa-
tients with brain damage can cause and worsen seborrheic
dermatitis.
The second most frequent diagnosis in these patients was my-
coses (15.5%) and the incidence was signiﬁcantly higher in the
group with severe brain injury (p< 0.01). This is most likely to be
induced by a prolonged period of being conﬁned to bed and the
treatment of patients with brain damage with multiple antibioticdrugs.8,9 A previous study reported that 9.5% of dermatology con-
sultations were requested for mycosis.2 The median time between
admission to hospital (with consequent immobilization in bed) and
the consultation for mycoses was 31.4 days (range 12e85 days). In a
previous study for decubitus candidiasis, the median time was 24.8
days.9
In our study, 13.2% of the patients were diagnosed with skin
eruption due to treatment with drugs. The prevalence of drug-
induced skin eruption is higher here than in a previous study,
which ranged from 4.2% to 10.5%.2 This is because patients with
Table 4 Severity of brain damage determined by Glasgow Coma Scale score.
Severe (8) Moderate (9e12) Mild (13)
Patients, n (%) 233 (68.3) 87 (25.5) 21 (6.2)
Three most common dermatological diseases,
% of patients
1. Mycoses (24.9) 1. Seborrheic dermatitis (20.6) 1. Seborrheic dermatitis (28.6)
2. Seborrheic dermatitis (20.6) 2. Pruritus (13.8) 2. Pruritus (14.3)
3. Drug eruption (18) 3. Drug eruption (12.6) 3. Herpes simplex (14.3)
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including anticonvulsant drugs, prophylactic antibiotics, antihy-
pertensive drugs, and diuretics. A life-threatening drug reaction,
such as toxic epidermal necrolysis (TEN) and StevenseJohnson
syndrome, can result from treatment with sulfonamide antibiotics
and the aromatic anticonvulsant drugs (e.g. carbamazepine,
phenytoin, phenobarbital, primidone, and oxcarbazepine), which
are often administered to patients with brain damage.10 It is widely
accepted that the latent period of a drug reaction is approximately
2e6 weeks (mean 2e4 weeks).11 The mean latency of drug-induced
skin eruption was 15 days (range 3e45 days) in our study.
Another common disorder in our study was xerosis cutis, which
occurred in 9.1% of patients. The incidence is higher than previous
studies of consultations with inpatients (2.8%).1,2,6 Xerosis is more
common in elderly patients and the mean SD age of our patients
with xerosis cutis was 76.5 5.1 years. Elderly patients are more
susceptible to xerosis due to pre-existing disease states, treatments,
and prescribed drugs. Some of these pre-existing conditions
include radiation, end-stage renal disease, nutritional deﬁciency
(especially zinc and essential fatty acids), thyroid disease, and
neurological disorders with decreased sweating, treatment with
antiandrogen drugs, treatment with diuretics, human immunode-
ﬁciency virus, and malignancies. Multiple individual factors may
contribute to xerosis cutis.
This study has a limitation in that many of the diagnoses were
performed only by clinical impression without taking a skin biopsy
sample or fungus culture. Also a computed tomography scan is
preferable to the GCS in evaluating the severity of brain damage.
Most of the patients included in our studywere in the acute stage of
brain damage. Over the past few years, several studies have
repeatedly shown that bullous pemphigoid is associated with
chronic neurological diseases, such as cerebrovascular disease,
dementia, multiple sclerosis, and Parkinson’s disease.12e16 It is
thought that bullous pemphigoid antigens or their isoforms in the
central nervous system may be exposed after a neurological insult
and may contribute to the generation of an immune response.17
However, our study did not study long-term dermatological prob-
lems in the chronic stages of brain damage and did not analyze any
molecular or immunological link between dermatological prob-
lems and neurological diseases. It was also unclear whether some
patients had a past history of dermatological disease, such as seb-
orrheic dermatitis, tinea pedis, or xerosis cutis. However, this study
does provide the information that dermatological disorders in pa-
tients with brain damage may become symptomatic and require a
consultation with a dermatologist.
In conclusion, we suggest that patients with brain damage are
more likely to have dermatological diseases than both the generalpopulation and inpatients in general. This is due to various reasons,
such as immobilization, treatment with multiple drugs, long-term
stays in hospital, and their immunocompromised status. Further-
more, brain damage and its treatment can release steroid hormones
and alter neuromediators, leading to an abnormal immune
response and an aggravating inﬂammatory response in the skin.
Although the exact mechanism has not been shown, the analysis of
dermatological disorders in patients with brain damage can pro-
vide a better understanding of the “braineskin connection”.References
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